Safety and Efficacy of the EndyMed Pro System Using RF Micro-needles Fractional Skin Remodeling

NCT ID: NCT02368626

Last Updated: 2015-02-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2016-01-31

Brief Summary

The need for cosmetic facial enhancement procedures with minimal down time and low risk has led to the development of methods for non-surgical skin rejuvenation. Various ablative lasers were developed, which remove the full skin surface in a controlled manner. However, the prolonged recovery and the significant risks prompted the development of fractional lasers which ablate the skin in a fractional manner, leaving untreated areas to improve healing process. In the past few years, fractional RF systems have been introduced that enable controlled skin resurfacing accompanied with dermal collagen remodeling. System using focused ultrasound , coagulating small volume of tissue in the dermis , have shown a lifting effect.8 Similar to these devices the EndyMed Pro™ System with RF Micro-Needles handpiece (INTENSIF) enables fractional skin coagulation with dermal heating for the reduction of wrinkles together with a lifting effect.

Conditions

Aging

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RF ablation treatment

'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction

Group Type: EXPERIMENTAL

EndyMed Pro™ RF Micro-Needles

Intervention Type: DEVICE

RF Micro-needles ablation treatments

Interventions

EndyMed Pro™ RF Micro-Needles

RF Micro-needles ablation treatments

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Healthy patients age 35-60 with facial condition as required by the treatment.
• Subjects with Fitzpatrick elasticity level of 4 and above
• Subject able to comprehend and sign informed consent for participation in this study.
• Subject must commit to all treatments and follow-up visits.
• Subjects must approve the use of their B&A photos by the doctor and EndyMed

Exclusion Criteria

• Subjects with implanted pacemakers, arrhythmias or any other electronic implanted device or severe known heart disorder
• Subjects with any implantable metal device in the treatment area.
• Subjects on any medication that would affect the characteristic of the skin (medical or hormonal), such as "Accutane", within the past 3 months.
• Subjects that have had any other invasive or noninvasive method of skin therapy hair removal, filers or Botox, performed in the past 3 months (in the treated area).
• Subjects who are scheduled or planned for any other invasive or noninvasive method of skin therapy in the treatment area at the period of the study.
• Subjects who have any form of suspicious lesion on the treatment area.
• Subjects with hypertrophic scarring, keloids, abnormal wound healing, as well as very dry and fragile skin.
• Pregnant or lactating Subjects.
• Subjects with Epilepsy or severe migraines.
• Subjects with permanent makeup/ tattoo/ body piercing (in the treated area).
• Subjects with any Infection / abscess / pains in treatment target area.
• History of any kind of cancer
• Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
• Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regime.
• Any surgical procedure in the treatment area within the last 3 months or before complete healing.
• Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
• Treating over the thyroid, breast or any other sensitive area.
• Subjects who suffer from autoimmune disorders or diabetes.
• Subjects using blood thinning medications.
• Subjects with clotting disorders.
• Subjects on drugs or psychologically determined unsuitable for the study.
• Subject is suffering extreme general weakness.
• Subject objects to the study protocol or unwilling to sign a consent form. Concurrent participation in any other clinical study.
• Any other condition that exclude the patient from the evaluation according to the physician judgment.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

EndyMed

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Gold, Dr

Role: PRINCIPAL_INVESTIGATOR

Tennessee Clinical Research Center, Nashville, Tennessee, USA

Mark Taylor, Dr

Role: PRINCIPAL_INVESTIGATOR

Gateway Aesthetic Institute and Laser Center, Salt Lake City, Utah, USA

Kenneth Rothaus, Dr

Role: PRINCIPAL_INVESTIGATOR

Ageless Plastic Surgery, New York, NY, USA

Yohei Tanaka, Dr

Role: PRINCIPAL_INVESTIGATOR

Clinica Tanaka Plastic and Reconstructive Surgery and Anti-aging Center, Tokyo, Japan

Central Contacts

Hanna Levy, Dr

Role: CONTACT

hanna@qsitemed.com

+972-52-2824966

Other Identifiers

EM-FR-01

Identifier Type: -

Identifier Source: org_study_id